Company Short-Term Debts: electrocore.com (ECOR)

electroCore, Inc. (ECOR) is scaling the application of non-invasive vagus nerve stimulation, focusing on expanding insurance reimbursements while protecting its technologies with patents. Short-term debt with maturities of up to one year demonstrates a financial burden, where the current level is approximately 0.00. The company is developing unique portable devices for migraine therapy, enabling the mitigation of chronic pain without the use of medication through physics.

The performance of this metric depends directly on the ability of electroCore, Inc. (ECOR) to generate cash flow to service its obligations, which is critical when scaling gammaCore digital therapy. This indicator captures the total amount of short-term loans due within a year, allowing for an assessment of liquidity gap risks through current loans and borrowings during the implementation of non-invasive vagus nerve stimulation systems.